(Bloomberg) -- Life-sciences company Danaher Corp. has stopped pursuing Catalent Inc. after expressing interest in buying the contract manufacturer, according to people familiar with the matter.
After Novo Holdings set the stage for a $16.5 billion buyout of contract manufacturing giant Catalent earlier this year, its ...
Fairfax County police released wild video of a "street takeover" that left one officer injured and a cruiser damaged last weekend. Hundreds of people gathered in Springfield, Virginia, at around 3 ...
Danaher Corporation is a leading player in the life science industry, with strong financial performance despite many spin-offs. The healthcare industry is facing challenges due to weak funding and ...
LONDON, April 12 (Reuters Breakingviews) - For any ambitious M&A adviser, there’s obvious appeal in pitching clients on a potential takeover of BP (BP.L) , opens new tab. The $110 billion energy ...
Danaher DHR has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 16.94%. Currently, Danaher has a market capitalization of $186.08 ...
Danaher (DHR) closed the most recent trading day at $251.47, moving +0.83% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day.
A month has gone by since the last earnings report for Danaher (DHR). Shares have added about 6.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...